NEW YORK, NY / ACCESSWIRE / August 15, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Yext, Inc. (NYSE:YEXT)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/yext-class-action-lawsuit?prid=30862&wire=1
Lead Plaintiff Deadline: August 16, 2022
Class Period: March 4, 2021 - March 8, 2022
Allegations against YEXT include that: (i) Yext's revenue and earnings were significantly deteriorating because of, among other things, poor sales execution and performance, as well as COVID-19 related disruptions; (ii) accordingly, Yext was unlikely to meet consensus estimates for its full year fiscal 2022 financial results and fiscal 2023 outlook; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Unity Software Inc. (NYSE:U)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/unity-software-lawsuit-submission-form?prid=30862&wire=1
Lead Plaintiff Deadline: September 6, 2022
Class Period: March 5, 2021 - May 10, 2022
Allegations against U include that: (i) deficiencies in Unity's product platform reduced the accuracy of the Company's machine learning technology; (ii) the foregoing was likely to have a material negative impact on the Company's revenues; (iii) accordingly, Unity had overstated the Company's commercial and/or financial prospects for 2022; (iv) as a result, the Company was likely to have to reduce its fiscal 2022 guidance; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
TG Therapeutics, Inc. (NASDAQ:TGTX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tgtx-lawsuit-loss-submission-form?prid=30862&wire=1
Lead Plaintiff Deadline: September 16, 2022
Class Period: January 15, 2020 - May 31, 2022
Allegations against TGTX include that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: